Author Archives: Admin

Drug repurposing patents: turning the obvious into the non-obvious

Drug repurposing, the development of new uses for existing drugs, is based significantly on method of use patents. That much is obvious. But for these patent applications to be granted, and defensible, they must be ‘non-obvious’, or surprising. Despite being based on literature evidence, the DrugRepurposing Online database is designed to do exactly that — […]

How is DrugRepurposing Online different from other, similar databases?

There have been recent developments in databases of value to drug repurposing like ChemBL and DrugBank. These are vast, free sources of information that repurposing can benefit from. But Drug Repuposing Online is different, and we wanted to tell you how it is a unique, and in our opinion, a more focused resource for repurposing, […]

Body of evidence in favour of calcium channel blockers for Alzheimer disease

While the effort to modify Alzheimer disease pathology by reducing the production of beta amyloid protein has largely been ineffective, there is a range of evidence that a widely used class of antihypertensive drug could provide a surprising benefit. Calcium antagonists are some of the most widely prescribed drugs for controlling blood pressure currently on […]

Retrospective analysis does not equate to prospective efficacy in drug trials for brain cancer

A variety of observational studies have been performed with respect to glioblastoma multiforme, the most lethal form of brain cancer, and the use of sodium valproate, an antiepileptic drug. Patients treated with sodium valproate for epilepsy have showed a improved outcome with respect to survival time and recurrence compared to patients treated with other antiepileptic...

This content is for Subscriber, 1 Week Member, 1 Month Membership and 1 Year Membership members only.
Log In Register

Three-fold improvement in Pharma R&D productivity with repurposing

In a recent analysis of the economics of pharmaceutical innovation, Grabowski and DiMasi calculated that out-of-pocket costs for a new chemical entity (NCE) were $1.395bn, compared to the costs for a ‘post-approval’ product of $466m. Accordingly, it may be possible to obtain three repurposed medicines for the investment in one new chemical entity. This is […]

Antidiabetic sulfonylureas for stroke

The antidiabetic sulfonylureas, which inhibit ATP-sensitive K+ (KATP) channels in pancreatic beta cells and stimulate insulin release in diabetes mellitus, mediate their effect on KATP channels via a high-affinity sulfonylurea receptor (SUR). But when looked at retrospectively in diabetic patients with ischemic stroke, patients treated with these drugs also seemd to be protected against stroke, […]